Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders

Connor, David; D.F., David; Joseph, Joanne

doi:10.1016/j.thromres.2013.09.009

Cited by 26 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with two previous studies . Leinhoe and colleagues studied bleeding and platelet reactivity in 50 patients with AML, prior to and 28 days after induction–remission chemotherapy .…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Agonist‐induced platelet reactivity correlates with bleeding in haemato‐oncological patients

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

“…Connor et al . reported that expression of P‐selectin was lower in patients with myelodysplastic syndrome compared with controls after in vitro platelet stimulation. The authors observed a trend for low expression of P‐selectin and bleeding history.…”

Section: Discussionmentioning

confidence: 98%

Agonist‐induced platelet reactivity correlates with bleeding in haemato‐oncological patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, PDMP assays may consist of quantifying assays, functional assays and morphologic assays. Although the ISTH report was a first step towards achieving standardization of assay methods for evaluating PDMPs, studies continue to use different assay types [24][25][26][27][28][29][30][31][32] . Strasser and coworkers showed a good correlation among three different methods of characterizing PDMPs and suggested that an analysis method other than FCM should be used concurrently to detect MPs when the PDMP size is below the limit of detection on FCM 24) .…”

Section: Discussionmentioning

confidence: 99%

Association of the Plasma Platelet-Derived Microparticles to Platelet Count Ratio with Hospital Mortality and Disseminated Intravascular Coagulopathy in Critically Ill Patients

Ohuchi

Fujino

Kishimoto

et al. 2015

J Atheroscler Thromb

View full text Add to dashboard Cite

Aim:The role of platelet-derived microparticles (PDMPs) in the crosstalk between coagulopathy and inflammation in critically ill patients remains unclear. The aim of this cohort observational study was to investigate the associations between the PDMP levels and hospital mortality or disseminated intravascular coagulopathy (DIC). Methods: This study included 119 patients who were admitted to the ICU. The PDMP levels were measured using an enzyme-linked immunosorbent assay three times a week, for a total of 372 samples. We calculated the maximum (max) PDMP value, max PDMP/platelet (PDMP/Plts) ratio (converted to the PDMP levels per 10 4 platelets) and nadir platelet count during the ICU stay. Baseline patient data and scores, including the Japanese Association for Acute Medicine (JAAM) DIC score, were collected, and potential predictors were analyzed for possible associations with hospital mortality. Results: The max PDMP/Plts ratio was significantly different comparing the survivors (n 98: median, 2.54) and non-survivors (n 21: median 17.59; p 0.001). There was a weak but statistically significant negative correlation between the max PDMP level and nadir platelet count (r 0.332, p 0.001). The max PDMP level and max PDMP/Plts ratio were higher in the DIC group (81.48 and 9.27, respectively) than in the non-DIC group (34.88 and 2.35, p 0.001 and p 0.001, respectively). The max PDMP/Plts ratio was the only variable found to be independently associated with hospital mortality according to a multivariate logistic regression analysis. Conclusions: PDMPs are involved in the development of DIC but are not related to hospital mortality. There is a good association between the PDMP/Plts ratio and hospital mortality and/or DIC in critically ill patients.

show abstract

“…In the study by Connor et al, patients with MDS did not show aberrant expression of activation markers (CD42b, PA-1, CD62p, and CD63 in unstimulated blood). In contrast, decreased ex vivo platelet activation in response to thrombin receptor activating peptide (TRAP), collagen related peptide (CRP), and adenosine diphosphate (ADP) was seen in MDS patients in comparison to healthy subjects [54]. In addition to abnormal expression of CD41, CD42c, and CD42b, Popov et al reported increased reactive oxygen species (ROS) production in platelets from MDS patients leading to platelet dysfunction [55].…”

Section: Can Flow Cytometry Provide Additional Diagnostic Informationmentioning

confidence: 99%

Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Porwit

2015

Curr Hematol Malig Rep

View full text Add to dashboard Cite

This review focuses on the most recent literature concerning flow cytometry (FCM) application for diagnosis of myelodysplastic syndrome (MDS). Aberrant FCM results have been defined as abnormalities in at least three tested features comprising at least two bone marrow (BM) cell compartments. FCM results should be interpreted together with the BM smear cytology, the morphological assessment of BM biopsy, and cytogenetic results. Including FCM in the pre-treatment assessment may provide not only diagnostic but also prognostic information. Further studies are needed to evaluate the role of FCM in individual risk assessment for MDS patients and in therapy choice and/or follow-up.

show abstract

Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders

Cited by 26 publications

References 21 publications

Agonist‐induced platelet reactivity correlates with bleeding in haemato‐oncological patients

Agonist‐induced platelet reactivity correlates with bleeding in haemato‐oncological patients

Association of the Plasma Platelet-Derived Microparticles to Platelet Count Ratio with Hospital Mortality and Disseminated Intravascular Coagulopathy in Critically Ill Patients

Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Contact Info

Product

Resources

About